- Login
- Register & Subscribe
- Language: EN FR DE
Finance, Grants, Deals
ProFibrix raises €8 million in Series B round
Monday 7 September 2009
ProFibrix BV of the Netherlands has raised €8 million in a Series B round enabling it to carry forward plans to seek FDA authorisation for a combined Phase 2/3 trial in the US of its candidate tissue sealant for use in surgery or trauma injury, Fibrocaps.
Location
Netherlands
Bid to take Celsis International private becomes unconditional
Thursday 3 September 2009
An investor in Celsis International Plc is on the verge of success in acquiring the drug toxicity detection company whose shares are listed on the London Stock Exchange. The investor is North Atlantic Value LLP (NAVLLP), part of the JO Hambro Capital Management Group.
Location
United Kingdom
Algeta to receive $61 million upfront for cancer drug
Thursday 3 September 2009
Algeta ASA is to receive $61 million upfront from Bayer Schering Pharma AG in a deal worth up to $800 million to develop and commercialise a radiopharmaceutical for bone metastases in patients with hormone-refractory prostate cancer.
Location
Norway
Norway supports Clavis with grant for pancreatic cancer trial
Monday 31 August 2009
The Norwegian government has awarded Clavis Pharma ASA up to $1.1 million to accelerate its early clinical-stage treatment for pancreatic cancer, intravenous CP-4126. The grant was made by Innovation Norway, a state-owned company.
Location
Norway
Santaris to receive $6.5 million for access to its locked nucleic acid drug platform
Sunday 30 August 2009
Santaris Pharma A/S is to receive $6.5 million upfront from Shire Plc for giving the UK company access to its locked nucleic acid (LNA) drug platform for identifying drug candidates against certain targets to treat rare genetic disorders.
Location
Denmark
Vernalis in $200 million oncology deal with GSK
Thursday 6 August 2009
Vernalis Plc said that it is entering an exclusive collaboration, option and licensing agreement with GlaxoSmithKline to research an undisclosed oncology target. The deal, including milestone payments, is valued at more than $200 million.
Location
United Kingdom
DiaGenic raises NOK 9.35 million in share placement
Wednesday 5 August 2009
DiaGenic ASA said that it has raised NOK 9.35 million ($1.54 million) through the placement of 2.5 million new shares with investors at a price of NOK 3.74 per share. The placement coincides with its plans to launch two diagnostic products in Europe.
Location
Norway
An investor in London-listed Celsis is taking the firm private
Monday 3 August 2009
An investor in Celsis International Plc, which makes products to detect drug toxicity, is taking the company private with a bid for the shares it does not already own pitched at 14.3% over the closing share price on 31 July 2009.
Location
United Kingdom
RXi Pharmaceuticals to raise $8.3 million
Friday 31 July 2009
A US company that is investigating therapeutics based on RNA interference (RNAi) has reached agreement with investors to raise $8.3 million in a public offering on Nasdaq. The company, RXi Pharmaceuticals Corp, went public in March 2008.
Location
United States
Lundbeck acquires LifeHealth Ltd for DKK 780 million
Tuesday 7 July 2009
Lundbeck A/S, which has a global franchise in drugs for the central nervous system, has acquired LifeHealth Ltd of the UK to increase its interest in the neurological drug, Xenazine (tetrabenazine), which was launched in the US in late 2008.
Location
Denmark
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013